Risk factors of hepatocellular carcinoma in patients with HBV-related liver cirrhosis receiving nucleos (t) ide analogues treatment
10.3760/cma.j.issn.1674-2397.2012.01.007
- VernacularTitle:乙型肝炎肝硬化患者核苷(酸)类药物治疗期间新发肝癌的危险因素分析
- Author:
Liuqing YANG
;
Guoli LIN
;
Yuankai WU
;
Xiangyong LI
;
Tingting XIONG
;
Zhiliang GAO
;
Yutian CHONG
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Liver cirrhosis;
Hepatitis B;
Nucleos(t) ide analogues;
Risk factors
- From:
Chinese Journal of Clinical Infectious Diseases
2012;05(1):28-32
- CountryChina
- Language:Chinese
-
Abstract:
Objective To survey the incidence of hepatocellular carcinoma (HCC) in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues treatment and to assess its risk factors.Methods A total of 141 patients with HBV-related liver cirrhosis receiving nucleos(t) ide therapy from April 2008 to June 2011 were enrolled.The clinical data including virological and biochemical tests were retrospectively analyzed.Univariate and multivariate Cox proportional hazards regression model was used to identify the risk factors of HCC occurrence.Results Patients were followed up for 6.4 to 87.6 months with a median followup time of 32.5 months.During the follow-up period,15 out of 141 patients developed HCC with an average annual incidence rate of 3.8％.HCC incidence was higher in HBeAg positive cirrhosis and in those with family history of liver cancer ( RR =4.524 and 3.858,P ＜ 0.05 ).Conclusions Patients with HBV-related cirrhosis have a high incidence rate of HCC even they recieve nucleos (t) ide analogues treatment.HBeAg positive cirrhosis and family history of liver cancer are independent risk factors for HCC.
